Last Updated: June 24, 2026

Suppliers and packagers for conzip


✉ Email this page to a colleague

« Back to Dashboard


conzip

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-689-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-689-30) 2015-06-22
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-690-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-690-30) 2015-06-22
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-691-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-691-30) 2015-06-22
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA Vertical Pharmaceuticals, LLC 68025-071-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (68025-071-30) 2011-09-20
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA Vertical Pharmaceuticals, LLC 68025-072-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (68025-072-30) 2011-09-20
Cipher Pharms Inc CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA Vertical Pharmaceuticals, LLC 68025-073-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (68025-073-30) 2011-09-20
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

CONZIP (celecoxib) Suppliers and Contract Manufacturing Landscape for Pharmaceutical Supply

Last updated: May 23, 2026

CONZIP is the brand name for celecoxib capsules (drug substance: celecoxib). Public-facing supplier and contract manufacturing details typically map to: (1) the celecoxib active pharmaceutical ingredient (API) supply chain, (2) capsule filling and packaging contract manufacturing organizations (CMOs), and (3) finished-dose distribution partners. The most reliable supplier references for CONZIP are FDA labeling, NDA/approved supplement manufacturing site disclosures, and trademark/labeler entities, but the specific supplier list cannot be produced from the information provided.

Who supplies the API for CONZIP (celecoxib)?

No complete, source-cited supplier roster can be stated for CONZIP’s celecoxib API from the information provided.

Celecoxib API sourcing: what to look for

  • NDA/labeler manufacturing site disclosures for the API or drug substance.
  • DMF-referenced API suppliers for celecoxib used by the approved finished product.
  • FDA inspection history and Form 483 records that name active ingredient sites, where available.

Which companies manufacture and package CONZIP capsules?

No complete, source-cited manufacturer and packager list can be stated for CONZIP from the information provided.

Finished dose manufacturing: typical data sources

  • Current FDA-approved labeling (Highlights of Prescribing Information and “Manufactured for” / “Distributed by” sections).
  • FDA Drugs@FDA approval records and manufacturing site listings for the NDA holder and supplements.
  • Orange Book product listings that may indicate application and manufacturer identifiers tied to the dosage form.

Who is the labeler of record for CONZIP?

No labeler-of-record statement can be made from the information provided.

Why labeler identification matters

The labeler entity on the product label often reflects:

  • NDA holder and/or marketing authorization holder for the commercial product
  • Distribution responsibility (marketing arm) versus actual manufacturing site ownership
  • Canada/US submission mapping when multiple jurisdictions use the same brand

What contract manufacturing (CMO) models are used for CONZIP?

No CMO model mapping can be stated from the information provided.

Common manufacturing structures for oral solid dose brands

  • API supplier to CMO for capsule filling (drug product manufacturing)
  • One CMO for drug product and a separate CMO for packaging
  • In-house packaging at a labeler’s facility with external capsule filling

How does CONZIP’s supply chain compare with other celecoxib brands?

No brand-to-brand supply chain comparison can be produced from the information provided.

Comparison targets

  • Drug product manufacturing sites
  • Packaging facilities
  • API or intermediate supplier ecosystems

What is the Orange Book and FDA status impact on suppliers for CONZIP?

No Orange Book-linked supplier constraints can be stated from the information provided.

Why exclusivity and listings matter

Supplier and site changes can be driven by:

  • Supplement approvals (manufacturing site changes, scale-up, process changes)
  • Patent and exclusivity status shifts that can alter commercial partners
  • Post-approval CMC changes that add/remove manufacturing sites

Key Takeaways

  • CONZIP is a celecoxib capsule product, so the supply chain logically includes celecoxib API sourcing plus capsule filling and packaging.
  • A complete and accurate list of CONZIP suppliers (API makers, CMOs, and labeler/distributor entities) cannot be produced from the information provided.

FAQs

  1. What does the CONZIP label typically identify as the manufacturer or distributor?
  2. How can I confirm the actual CONZIP manufacturing site from FDA sources?
  3. Do Orange Book listings identify CONZIP’s contract manufacturing organizations?
  4. How do FDA manufacturing site changes affect CONZIP supplier eligibility?
  5. What supplier risks arise when celecoxib API is sourced from multiple vendors?

References

  1. FDA Drugs@FDA. Product-specific pages and labeling records for CONZIP (celecoxib).
  2. FDA Orange Book. Application and listed drug details for CONZIP.
  3. FDA Approved Labeling (package insert) for CONZIP capsules.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.